https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Approves REMS Modification for Sparsentan in IgA Nephropathy

FDA Approves REMS Modification for Sparsentan in IgA Nephropathy

The FDA updated sparsentan’s REMS, easing monitoring requirements, enhancing treatment access for IgA nephropathy patients, and supporting kidney function preservation.

administrator

Related Articles